UnknownPhase 2NCT01849939

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Clermont-Ferrand
Principal Investigator
Olivier Tournilhac
University Hospital, Clermont-Ferrand
Intervention
Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)(drug)
Enrollment
43 enrolled
Eligibility
18-70 years · All sexes
Timeline
2012 – 2017

Study locations (1)

Collaborators

Pierre Fabre Laboratories

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01849939 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials